NR1D1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-09. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
2 MoS2 + 7 O2 → 2 MoO3 + 4 SO2 The trioxide, which is volatile at high temperatures, is the precursor to virtually all other Mo compounds as well as alloys. Molybdenum has several oxidation states, the most stable being +4 and +6 (bolded in the table at left). Molybdenum(VI) oxide is soluble in strong alkaline water, forming molybdates (MoO42−). Molybdates are weaker oxidants than chromates. They tend to form structurally complex oxyanions by condensation at lower pH values, such as [Mo7O24]6− and [Mo8O26]4−. Polymolybdates can incorporate other ions, forming polyoxometalates. The dark-blue phosphorus-containing heteropolymolybdate P[Mo12O40]3− is used for the spectroscopic detection of phosphorus. The broad range of oxidation states of molybdenum is reflected in various molybdenum chlorides:
Several of Kissinger's own staff, most notably John Negroponte, were strongly opposed to him accepting this offer, saying Kissinger had given away more than he had obtained. In response to Negronponte's objections, Kissinger exploded in rage, accusing him of "nit-picking" and screamed at the top of his voice: "You don't understand. I want to meet their terms. I want to reach an agreement. I want to end this war before the election. It can be done and it will be done. What do you want us to do? Stay there forever?" Kissinger told Tho that he would go to Washington and Saigon to get the approval of Nixon and Thieu, and he expected the agreement to be signed on either 25 October or 26 October. On 12 October, Kissinger told Nixon: "Well, you've got three for three, Mr. President"—meaning trips to China and the Soviet Union plus a peace agreement for Vietnam. Even the fact that under the peace agreement, the United States was to pay reparations to North Vietnam in the form of economic aid was seen as a benefit by Nixon, who commented that this would be a way of forcing the Vietnamese Communists to admit to the economic failures of their system.
A complete blood count (CBC), also known as a full blood count (FBC) or full haemogram (FHG), is a set of medical laboratory tests that provide information about the cells in a person's blood. The CBC indicates the counts of white blood cells, red blood cells and platelets, the concentration of hemoglobin, and the hematocrit (the volume percentage of red blood cells). The red blood cell indices, which indicate the average size and hemoglobin content of red blood cells, are also reported, and a white blood cell differential, which counts the different types of white blood cells, may be included. The CBC is often carried out as part of a medical assessment and can be used to monitor health or diagnose diseases. The results are interpreted by comparing them to reference ranges, which vary with sex and age. Conditions like anemia and thrombocytopenia are defined by abnormal complete blood count results. The red blood cell indices can provide information about the cause of a person's anemia such as iron deficiency and vitamin B12 deficiency, and the results of the white blood cell differential can help to diagnose viral, bacterial and parasitic infections and blood disorders like leukaemia. Not all results falling outside of the reference range require medical intervention. The CBC is usually performed by an automated hematology analyzer, which counts cells and collects information on their size and structure. The concentration of hemoglobin is measured, and the red blood cell indices are calculated from measurements of red blood cells and hemoglobin.
Sources: en.wikipedia.org
==== Arsenic-based drugs ==== Despite, or possibly because of, its long-known toxicity, arsenic-containing potions and drugs have a history in medicine and quackery that continues into the 21st century. Starting in the early 19th century and continuing into the 20th century, Fowler's solution, a toxic concoction of sodium arsenite, was sold. The organoarsenic compound Salvarsan was the first synthetic chemotherapeutic agent, discovered by Paul Ehrlich. The treatment, however, led to many problems causing long lasting health complications. Around 1943 it was finally superseded by penicillin. The related drug Melarsoprol is still in use against late-state African trypanosomiasis (sleeping sickness), despite the substance's possibly fatal side effects. Arsenic trioxide (As2O3) inhibits cell growth and induces apoptosis (programmed cell death) in certain types of cancer cells, which are normally immortal and can multiply without limit. Arsenic trioxide-induced necrosis has been shown to provoke immune activation through release of damage-associated molecular patterns (DAMPs). In combination with all-trans retinoic acid, it is FDA-approved as first-line treatment for promyelocytic leukemia.
The following year a formal statement was issued to the General Assembly which proclaimed that South Africa had no intention of complying with trusteeship, nor was it obligated to release new information or reports pertaining to its administration. Simultaneously, the South West Africa Affairs Administration Act, 1949, was passed by South African parliament. The new legislation gave white South West Africans parliamentary representation and the same political rights as white South Africans. The UN General Assembly responded by deferring to the International Court of Justice (ICJ), which was to issue an advisory opinion on the international status of South West Africa. The ICJ ruled that South West Africa was still being governed as a mandate; hence, South Africa was not legally obligated to surrender it to the UN trusteeship system if it did not recognise the mandate system had lapsed. Conversely, however, it was still bound by the provisions of the original mandate. Adherence to the original mandate meant South Africa could not unilaterally modify the international status of South West Africa. Malan and his government rejected the court's opinion as irrelevant. The UN formed a Committee on South West Africa, which issued its own independent reports regarding the administration and development of that territory. The Committee's reports became increasingly scathing of South African officials when the National Party imposed its harsh system of racial segregation and stratification—apartheid—on South West Africa.
mitotic rounding The process by which most animal cells undergo an overall change in shape during or preceding mitosis, abandoning the various complex or elongated shapes characteristic of interphase and rapidly contracting into a rounded or spherical morphology that is more conducive to cell division. This phenomenon has been observed both in vivo and in vitro.
Most polyphenols are metabolized by catechol-O-methyltransferase, and therefore do not have the chemical structure allowing antioxidant activity in vivo; they may exert biological activity as signaling molecules.
Sources: en.wikipedia.org
=== Australia === In Australia, medical laboratory scientists complete a four-year undergraduate degree program in medical science, medical laboratory science or laboratory medicine. These programs should be accredited by the Australian Institute of Medical and Clinical Scientists (AIMS).
Importantly, the NPYS group can replace the Acm PG to yield an activated thiol. Using this method, Kiso and coworkers reported the first total synthesis of insulin in 1993. In this work, the A-chain of insulin was prepared with following protecting groups in place on its cysteines: CysA6(But), CysA7(Acm), and CysA11(But), leaving CysA20 unprotected.
In 2024, Dalman and colleagues described the remains of a tyrannosaur discovered in 1983 in the Campanian-early Maastrichtian Hall Lake Formation in New Mexico. Reposited at the New Mexico Museum of Natural History and Science, the fossil material (NMMNH P-3698) consists of the right postorbital, right squamosal, left palatine, and an incomplete maxilla from the skull, the left dentary, right splenial, right prearticular, right angular and right articular from the lower jaws, isolated teeth, and chevrons. Some of the bones were briefly mentioned in 1984 as belonging to T. rex, and described in 1986. Lehman and Carpenter (1990) suggested that NMMNH P-3698 belonged to a new tyrannosaurid genus, while Carr and Williamson (2000) disagreed with their claim. Sullivan and Lucas (2015) argued that there is little evidence to support NMMNH P-3698 as a specimen of Tyrannosaurus rex, so they tentatively classified it as cf. Tyrannosaurus sp.; they also considered that the McRae tyrannosaur lived before the Lancian (before 67 million years ago) based on its probable association with the Alamosaurus fossil.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.